Helen M. Blau

Administrative Appointments

• Director, Baxter Laboratory for Stem Cell Biology , (2000– present )
• Member, Institute for Stem Cell Biology and Regenerative Medicine , (2004– present )
• Faculty Affiliate, Bio-X Program , (2005– present )
• Faculty Affidiate, Stanford Cardiovascular Institute , (2003– present )
• Chair, Department of Molecular Pharmacology , (1997– 2002 )

Honors and Awards

• Fulbright Senior Specialist, Institut Pasteur, Paris (2007)
• Board Member, Harvard Board of Overseer’s (2004-2010)
• Council Member, Institute of Medicine (IOM) (2003-2009)
• Plenary Lecturer, 400th Pontifical Academy, The Vatican (2003)
• Honorary Doctorate, University of Nijmegen, Holland (2003)
• Rolf-Sammet-Fonds Visiting Professorship, University of Frankfurt (2003)
• President, International Society of Differentiation (2002-2004)
• Council Member, American Society for Cell Biology (2002-2004)
• Director's Lectureship, NIH (2000)
• Board Member, American Society for Gene Therapy (1999-2002)
• Donald E. and Delia B. Baxter Endowed Professorship, Stanford University (1999)
• Merit Award, National Institute of Health (1995-2005)
• Council Member, National Institute on Aging, NIH (1996-2000)
• Elected Fellow, American Academy of Arts and Sciences (1996)
• Elected Member, Institute of Medicine, National Academy of Arts and Sciences (1995)
• FASEB Excellence in Science Award, FASEB (1999)
• Yvette Mayent-Rothschild Visiting Professor, Instituts Curie and Pasteur, Paris (1995)
• Nobel Forum Lectureship, Karolinska Institute, Sweden (1995)
• President, American Society for Developmental Biology (1994-1995)
• Senior Career Recognition Award, Women in Cell Biology, ASCB (1992)
• Elected Fellow, American Association for the Advancement of Science (1991)

Professional Education

• Ph.D., Harvard University (1975)
• M.A., Harvard University (1970)
• B.A., University of York (1969)

Postdoctoral Advisees

• Penney Gilbert

Graduate & Fellowship Program Affiliations

• Cancer Biology
• Microbiology and Immunology
• Neurology and Neurol Sciences
• Neonatology and Developmental Biology

Web Site Links

• Blau Lab Website

Research Interests

The question of fundamental interest to our laboratory is how cells maintain a quiescent, proliferative or differentiated state. Once a cell becomes specialized for function in a particular tissue, that differentiated state is stable, yet the molecular mechanisms that control the expression of its characteristic repertoire of genes are largely dynamic. Our research is directed at understanding this apparent paradox and elucidating the nature of cell memory and cell plasticity. By perturbing the intracellular or extracellular milieu, we are probing the regulatory network that determines cell fate and how it can be altered. This knowledge is key to our understanding of stem cell quiescence, self-renewal, differentiation, and how cancer arises. This information is also critical to the use of somatic cells or stem cells for therapeutic purposes.

Stem Cell Biology in Bioengineered Niches: we are using nanotechnology to study the role of extrinsic tethered and soluble factors in stem cell fate determination and self-renewal. Specifically, we are studying the effects over time of soluble components (growth factors, morphogens and cytokines) and tethered insoluble components (cell-cell adhesion and extracellular matrix components) on apoptosis, cell division, and differentiation of live single cells in hydrogel microwells by time lapse microscopy. We are elucidating the cell intrinsic molecular mechanisms that govern nuclear reprogramming critical to directing adult stem cell differentiation for use in cell based therapies. To study chromatin remodeling mechanisms necessary for reprogramming, we are using cell fusion and nuclear transfer approaches.

Technology Development for Elucidation of Regulatory Pathways: using technologies developed in our laboratory (restriction enzyme generated siRNAs (REGS) for loss of function analyses and beta-galactosidase assays of protein complementation for monitoring intracellular protein translocation, membrane receptor protein interactions, and non-invasive in vivo imaging, we are determining the molecular bases (chromatin remodeling and signaling pathways) for changing the nuclear function of embryonic and adult stem cells.

Other Recent Work: our laboratory has worked in a broad range of research disciplines in the past. Most recently, we have studied the RNAi pathway and angiogenesis. Members of our lab have developed a technology to generate shRNA libraries. In addition, we have helped to understand better how the RNA interference pathway operates. Angiogenesis is a critical component of stroke, head injury, vascular malformations, development and brain tumor growth to name a few. Recently we have found a means for enhancing VEGF's beneficial effects while abrogating its deleterious effects.

Publications

• A home away from home: challenges and opportunities in engineering in vitro muscle satellite cell niches. Cosgrove BD,  Sacco A, Gilbert PM, Blau HM.  Differentiation.  2009 Sep-Oct; 78 (2-3): 185-94
• Reprogramming to a muscle fate by fusion recapitulates differentiation. Pomerantz JH,  Mukherjee S, Palermo AT, Blau HM.  J Cell Sci.  2009; 122 (Pt 7): 1045-53
• Nuclear reprogramming in heterokaryons is rapid, extensive, and bidirectional. Palermo A,  Doyonnas R, Bhutani N, Pomerantz J, Alkan O, Blau HM.  FASEB J.  2009; 23 (5): 1431-40
• Cell therapies for muscular dystrophy. Blau HM,  N Engl J Med.  2008; 359 (13): 1403-5
• Self-renewal and expansion of single transplanted muscle stem cells. Sacco A,  Doyonnas R, Kraft P, Vitorovic S, Blau HM.  Nature.  2008; 456 (7221): 502-6
• Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. Johansson CB,  Youssef S, Koleckar K, Holbrook C, Doyonnas R, Corbel SY, Steinman L, Rossi FM, Blau HM.  Nat Cell Biol.  2008; 10 (5): 575-83
• Myoblasts and macrophages share molecular components that contribute to cell-cell fusion. Pajcini KV,  Pomerantz JH, Alkan O, Doyonnas R, Blau HM.  J Cell Biol.  2008; 180 (5): 1005-19
• Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells. Streetz KL,  Doyonnas R, Grimm D, Jenkins DD, Fuess S, Perryman S, Lin J, Trautwein C, Shizuru J, Blau H, Sylvester KG, Kay MA.  Hepatology.  2008; 47 (2): 706-18
• In vivo optical bioluminescence imaging of collagen-supported cardiac cell grafts. Kutschka I,  Chen IY, Kofidis T, von Degenfeld G, Sheikh AY, Hendry SL, Hoyt G, Pearl J, Blau HM, Gambhir SS, Robbins RC.  J Heart Lung Transplant.  2007; 26 (3): 273-80
• Anne McLaren (1927-2007). Blau HM,  Differentiation.  2007; 75 (10): 899-901
• A universal technology for monitoring G-protein-coupled receptor activation in vitro and noninvasively in live animals. von Degenfeld G,  Wehrman TS, Hammer MM, Blau HM.  FASEB J.  2007; 21 (14): 3819-26
• A novel enzyme complementation-based assay for monitoring G-protein-coupled receptor internalization. Hammer MM,  Wehrman TS, Blau HM.  FASEB J.  2007; 21 (14): 3827-34
• Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Blum G,  von Degenfeld G, Merchant MJ, Blau HM, Bogyo M.  Nat Chem Biol.  2007; 3 (10): 668-77
• Increased host neuronal survival and motor function in BMT Parkinsonian mice: involvement of immunosuppression. Keshet GI,  Tolwani RJ, Trejo A, Kraft P, Doyonnas R, Clayberger C, Weimann JM, Blau HM.  J Comp Neurol.  2007; 504 (6): 690-701
• Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. Wan DC,  Pomerantz JH, Brunet LJ, Kim JB, Chou YF, Wu BM, Harland R, Blau HM, Longaker MT.  J Biol Chem.  2007; 282 (36): 26450-9
• Active tissue-specific DNA demethylation conferred by somatic cell nuclei in stable heterokaryons. Zhang F,  Pomerantz JH, Sen G, Palermo AT, Blau HM.  Proc Natl Acad Sci U S A.  2007; 104 (11): 4395-400
• Localization of vascular response to VEGF is not dependent on heparin binding. Springer ML,  Banfi A, Ye J, von Degenfeld G, Kraft PE, Saini SA, Kapasi NK, Blau HM.  FASEB J.  2007; 21 (9): 2074-85
• Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Wehrman T,  He X, Raab B, Dukipatti A, Blau H, Garcia KC.  Neuron.  2007; 53 (1): 25-38
• Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Kutschka I,  Chen IY, Kofidis T, Arai T, von Degenfeld G, Sheikh AY, Hendry SL, Pearl J, Hoyt G, Sista R, Yang PC, Blau HM, Gambhir SS, Robbins RC.  Circulation.  2006; 114 (1 Suppl): I167-73
• Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. von Degenfeld G,  Banfi A, Springer ML, Wagner RA, Jacobi J, Ozawa CR, Merchant MJ, Cooke JP, Blau HM.  FASEB J.  2006; 20 (14): 2657-9
• A brief history of RNAi: the silence of the genes. Sen GL,  Blau HM.  FASEB J.  2006; 20 (9): 1293-9
• A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Wehrman TS,  Raab WJ, Casipit CL, Doyonnas R, Pomerantz JH, Blau HM.  Proc Natl Acad Sci U S A.  2006; 103 (50): 19063-8
• Luminescent imaging of beta-galactosidase activity in living subjects using sequential reporter-enzyme luminescence. Wehrman TS,  von Degenfeld G, Krutzik PO, Nolan GP, Blau HM.  Nat Methods.  2006; 3 (4): 295-301
• Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts. Kutschka I,  Kofidis T, Chen IY, von Degenfeld G, Zwierzchoniewska M, Hoyt G, Arai T, Lebl DR, Hendry SL, Sheikh AY, Cooke DT, Connolly A, Blau HM, Gambhir SS, Robbins RC.  Circulation.  2006; 114 (1 Suppl): I174-80
• Optimizing techniques for tracking transplanted stem cells in vivo. Brazelton TR,  Blau HM.  Stem Cells.  2005; 23 (9): 1251-65
• Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Jacobi J,  Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, Patterson AJ, Kimoto M, Blau HM, Cooke JP.  Circulation.  2005; 111 (11): 1431-8
• IGF-I increases bone marrow contribution to adult skeletal muscle and enhances the fusion of myelomonocytic precursors. Sacco A,  Doyonnas R, LaBarge MA, Hammer MM, Kraft P, Blau HM.  J Cell Biol.  2005; 171 (3): 483-92
• Bone marrow contribution to skeletal muscle: a physiological response to stress. Palermo AT,  Labarge MA, Doyonnas R, Pomerantz J, Blau HM.  Dev Biol.  2005; 279 (2): 336-44
• Enzymatic detection of protein translocation. Wehrman TS,  Casipit CL, Gewertz NM, Blau HM.  Nat Methods.  2005; 2 (7): 521-7
• mRNA translation is not a prerequisite for small interfering RNA-mediated mRNA cleavage. Sen GL,  Wehrman TS, Blau HM.  Differentiation.  2005; 73 (6): 287-93
• Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies. Sen GL,  Blau HM.  Nat Cell Biol.  2005; 7 (6): 633-6
• Hematopoietic contribution to skeletal muscle regeneration by myelomonocytic precursors. Doyonnas R,  LaBarge MA, Sacco A, Charlton C, Blau HM.  Proc Natl Acad Sci U S A.  2004; 101 (37): 13507-12
• Nuclear reprogramming: a key to stem cell function in regenerative medicine. Pomerantz J,  Blau HM.  Nat Cell Biol.  2004; 6 (9): 810-6
• Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. Ozawa CR,  Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, McDonald DM, Blau HM.  J Clin Invest.  2004; 113 (4): 516-27
• Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis. Jacobi J,  Tam BY, Sundram U, von Degenfeld G, Blau HM, Kuo CJ, Cooke JP.  Gene Ther.  2004; 11 (3): 302-9
• Restriction enzyme-generated siRNA (REGS) vectors and libraries. Sen G,  Wehrman TS, Myers JW, Blau HM.  Nat Genet.  2004; 36 (2): 183-9
• Hematopoietic contribution to skeletal muscle regeneration by myelomonocytic precursors. Doyonnas R,  LaBarge MA, Sacco A, Charlton C, Blau HM.  PNAS.  2004; 100 (37): 13507-13512
• Nuclear reprogramming: a key to stem cell function in regenerative medicine. Pomerantz, J,  Blau, HM.  Nature Cell Biology.  2004; 6 (9): 810-816
• Restriction enzyme-generated siRNA (REGS) vectors and libraries. Sen, G,  Wehrman TS, Myers JW, Blau HM..  Nature Genetics.  2004; 36 (2): 183-9
• Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant. Weimann JM,  Johansson CB, Trejo A, Blau HM.  Nat Cell Biol.  2003; 5 (11): 959-66
• Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis. von Degenfeld G,  Banfi A, Springer ML, Blau HM.  Br J Pharmacol.  2003; 140 (4): 620-6
• Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. Weimann JM,  Charlton CA, Brazelton TR, Hackman RC, Blau HM.  PNAS.  2003; 100 (4): 2088-93
• Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant. Weimann JM,  Johansson CB, Trejo A, Blau HM.  Nature Cell Biology.  2003; 5 (11): 959 - 966
• Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. Weimann JM,  Charlton CA, Brazelton TR, Hackman RC, Blau HM.  Proc Natl Acad Sci U S A.  2003; 100 (4): 2088-93
• Localized arteriole formation directly adjacent to the site of VEGF-induced angiogenesis in muscle. Springer ML,  Ozawa CR, Banfi A, Kraft PE, Ip TK, Brazelton TR, Blau HM.  Mol Ther.  2003; 7 (4): 441-9
• Significant differences among skeletal muscles in the incorporation of bone marrow-derived cells. Brazelton TR,  Nystrom M, Blau HM.  Dev Biol.  2003; 262 (1): 64-74
• Gene delivery to muscle. Springer ML,  Rando TA, Blau HM.  Curr Protoc Hum Genet.  2002; Chapter 13 Unit13.4
• Transient production of alpha-smooth muscle actin by skeletal myoblasts during differentiation in culture and following intramuscular implantation. Springer ML,  Ozawa CR, Blau HM.  Cell Motil Cytoskeleton.  2002; 51 (4): 177-86
• RIP2, a checkpoint in myogenic differentiation. Munz B,  Hildt E, Springer ML, Blau HM.  Mol Cell Biol.  2002; 22 (16): 5879-86
• Myoblast-mediated gene transfer for therapeutic angiogenesis. Banfi A,  Springer ML, Blau HM.  Methods Enzymol.  2002; 346 145-57
• VEGF gene delivery for treatment of ischemic cardiovascular disease. Koransky ML,  Robbins RC, Blau HM.  Trends Cardiovasc Med.  2002; 12 (3): 108-14
• Protein-protein interactions monitored in mammalian cells via complementation of beta -lactamase enzyme fragments. Wehrman T,  Kleaveland B, Her JH, Balint RF, Blau HM.  Proc Natl Acad Sci U S A.  2002; 99 (6): 3469-74
• In vivo monitoring of myoblast transplantation into rat myocardium. Koransky ML,  Ip TK, Wu S, Cao Y, Berry G, Contag C, Blau H, Robbins R.  J Heart Lung Transplant.  2001; 20 (2): 188-189
• Not the usual suspects: the unexpected sources of tissue regeneration. Springer ML,  Brazelton TR, Blau HM.  J Clin Invest.  2001; 107 (11): 1355-6
• Laminin-induced change in conformation of preexisting alpha7beta1 integrin signals secondary myofiber formation. Blanco-Bose WE,  Blau HM.  Dev Biol.  2001; 233 (1): 148-60
• Purification of mouse primary myoblasts based on alpha 7 integrin expression. Blanco-Bose WE,  Yao CC, Kramer RH, Blau HM.  Exp Cell Res.  2001; 265 (2): 212-20
• The evolving concept of a stem cell: entity or function? Blau HM,  Brazelton TR, Weimann JM.  Cell.  2001; 105 (7): 829-41
• Neural cell adhesion molecule (NCAM) and myoblast fusion. Charlton CA,  Mohler WA, Blau HM.  Dev Biol.  2000; 221 (1): 112-9
• Interaction blues: protein interactions monitored in live mammalian cells by beta-galactosidase complementation. Rossi FM,  Blakely BT, Blau HM.  Trends Cell Biol.  2000; 10 (3): 119-22
• Epidermal growth factor receptor dimerization monitored in live cells. Blakely BT,  Rossi FM, Tillotson B, Palmer M, Estelles A, Blau HM.  Nat Biotechnol.  2000; 18 (2): 218-22
• A novel means of drug delivery: myoblast-mediated gene therapy and regulatable retroviral vectors. Ozawa CR,  Springer ML, Blau HM.  Annu Rev Pharmacol Toxicol.  2000; 40 295-317
• Angiogenesis monitored by perfusion with a space-filling microbead suspension. Springer ML,  Ip TK, Blau HM.  Mol Ther.  2000; 1 (1): 82-7
• Transcriptional control: rheostat converted to on/off switch. Rossi FM,  Kringstein AM, Spicher A, Guicherit OM, Blau HM.  Mol Cell.  2000; 6 (3): 723-8
• From marrow to brain: expression of neuronal phenotypes in adult mice. Brazelton TR,  Rossi FM, Keshet GI, Blau HM.  Science.  2000; 290 (5497): 1775-9
• Monitoring protein-protein interactions in live mammalian cells by beta-galactosidase complementation. Rossi FM,  Blakely BT, Charlton CA, Blau HM.  Methods Enzymol.  2000; 328 231-51
• The phosphoprotein protein PEA-15 inhibits Fas- but increases TNF-R1-mediated caspase-8 activity and apoptosis. Estellés A,  Charlton CA, Blau HM.  Dev Biol.  1999; 216 (1): 16-28
• Analysis of immune responses to varicella zoster viral proteins induced by DNA vaccination. Abendroth A,  Slobedman B, Springer ML, Blau HM, Arvin AM.  Antiviral Res.  1999; 44 (3): 179-92
• Tet B or not tet B: advances in tetracycline-inducible gene expression. Blau HM,  Rossi FM.  Proc Natl Acad Sci U S A.  1999; 96 (3): 797-9
• Plasticity of cell fate: insights from heterokaryons. Blau HM,  Blakely BT.  Semin Cell Dev Biol.  1999; 10 (3): 267-72
• Graded transcriptional response to different concentrations of a single transactivator. Kringstein AM,  Rossi FM, Hofmann A, Blau HM.  Proc Natl Acad Sci U S A.  1998; 95 (23): 13670-5
• VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Springer ML,  Chen AS, Kraft PE, Bednarski M, Blau HM.  Mol Cell.  1998; 2 (5): 549-58
• Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. Rossi FM,  Guicherit OM, Spicher A, Kringstein AM, Fatyol K, Blakely BT, Blau HM.  Nat Genet.  1998; 20 (4): 389-93
• Recent advances in inducible gene expression systems. Rossi FM,  Blau HM.  Curr Opin Biotechnol.  1998; 9 (5): 451-6
• Highly conserved RNA sequences that are sensors of environmental stress. Spicher A,  Guicherit OM, Duret L, Aslanian A, Sanjines EM, Denko NC, Giaccia AJ, Blau HM.  Mol Cell Biol.  1998; 18 (12): 7371-82
• Inhibition of solid tumor growth by Fas ligand-expressing myoblasts. Springer ML,  Kraft PE, Blau HM.  Somat Cell Mol Genet.  1998; 24 (5): 281-9
• High-efficiency retroviral infection of primary myoblasts. Springer ML,  Blau HM.  Somat Cell Mol Genet.  1997; 23 (3): 203-9
• Methods for myoblast transplantation. Rando TA,  Blau HM.  Methods Cell Biol.  1997; 52 261-72
• Death of solid tumor cells induced by Fas ligand expressing primary myoblasts. Hofmann A,  Blau HM.  Somat Cell Mol Genet.  1997; 23 (4): 249-57
• Monitoring protein-protein interactions in intact eukaryotic cells by beta-galactosidase complementation. Rossi F,  Charlton CA, Blau HM.  Proc Natl Acad Sci U S A.  1997; 94 (16): 8405-10
• Fusion competence of myoblasts rendered genetically null for N-cadherin in culture. Charlton CA,  Mohler WA, Radice GL, Hynes RO, Blau HM.  J Cell Biol.  1997; 138 (2): 331-6
• Gene expression and cell fusion analyzed by lacZ complementation in mammalian cells. Mohler WA,  Blau HM.  Proc Natl Acad Sci U S A.  1996; 93 (22): 12423-7
• Myoblast-mediated expression of colony stimulating factor-1 (CSF-1) in the cytokine-deficient op/op mouse. Dhawan J,  Rando TA, Elson SE, Lee F, Stanley ER, Blau HM.  Somat Cell Mol Genet.  1996; 22 (5): 363-81
• Defective myogenesis in NFB-s mutant associated with a saturable suppression of MYF5 activity. Rohrer DK,  Blau HM.  Somat Cell Mol Genet.  1996; 22 (5): 349-61
• Spectrophotometric quantitation of tissue culture cell number in any medium. Mohler WA,  Charlton CA, Blau HM.  Biotechniques.  1996; 21 (2): 260-2, 264, 266
• Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Hofmann A,  Nolan GP, Blau HM.  Proc Natl Acad Sci U S A.  1996; 93 (11): 5185-90
• Gene therapy--a novel form of drug delivery. Blau HM,  Springer ML.  N Engl J Med.  1995; 333 (18): 1204-7
• The fate of myoblasts following transplantation into mature muscle. Rando TA,  Pavlath GK, Blau HM.  Exp Cell Res.  1995; 220 (2): 383-9
• Tetracycline-regulated gene expression following direct gene transfer into mouse skeletal muscle. Dhawan J,  Rando TA, Elson SL, Bujard H, Blau HM.  Somat Cell Mol Genet.  1995; 21 (4): 233-40
• Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers. Pavlath GK,  Rando TA, Blau HM.  J Cell Biol.  1994; 127 (6 Pt 2): 1923-32
• Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. Gussoni E,  Pavlath GK, Miller RG, Panzara MA, Powell M, Blau HM, Steinman L.  J Immunol.  1994; 153 (10): 4798-805
• Fast myosin heavy chains expressed in secondary mammalian muscle fibers at the time of their inception. Cho M,  Hughes SM, Karsch-Mizrachi I, Travis M, Leinwand LA, Blau HM.  J Cell Sci.  1994; 107 ( Pt 9) 2361-71
• Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. Rando TA,  Blau HM.  J Cell Biol.  1994; 125 (6): 1275-87
• Membrane-bound neomycin phosphotransferase confers drug-resistance in mammalian cells: a marker for high-efficiency targeting of genes encoding secreted and cell-surface proteins. Mohler WA,  Blau HM.  Somat Cell Mol Genet.  1994; 20 (3): 153-62
• Tumor suppression by RNA from the 3' untranslated region of alpha-tropomyosin. Rastinejad F,  Conboy MJ, Rando TA, Blau HM.  Cell.  1993; 75 (6): 1107-17
• Myoblasts in pattern formation and gene therapy. Blau HM,  Dhawan J, Pavlath GK.  Trends Genet.  1993; 9 (8): 269-74
• Genetic complementation reveals a novel regulatory role for 3' untranslated regions in growth and differentiation. Rastinejad F,  Blau HM.  Cell.  1993; 72 (6): 903-17
• Evidence for myoblast-extrinsic regulation of slow myosin heavy chain expression during muscle fiber formation in embryonic development. Cho M,  Webster SG, Blau HM.  J Cell Biol.  1993; 121 (4): 795-810
• Three slow myosin heavy chains sequentially expressed in developing mammalian skeletal muscle. Hughes SM,  Cho M, Karsch-Mizrachi I, Travis M, Silberstein L, Leinwand LA, Blau HM.  Dev Biol.  1993; 158 (1): 183-99
• Muscle fiber pattern is independent of cell lineage in postnatal rodent development. Hughes SM,  Blau HM.  Cell.  1992; 68 (4): 659-71
• Cloning muscle isoforms of neural cell adhesion molecule using an episomal shuttle vector. Pan LC,  Margolskee RF, Blau HM.  Somat Cell Mol Genet.  1992; 18 (2): 163-77
• Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Gussoni E,  Pavlath GK, Lanctot AM, Sharma KR, Miller RG, Steinman L, Blau HM.  Nature.  1992; 356 (6368): 435-8
• Beta-enolase is a marker of human myoblast heterogeneity prior to differentiation. Peterson CA,  Cho M, Rastinejad F, Blau HM.  Dev Biol.  1992; 151 (2): 626-9
• Differentiation requires continuous active control. Blau HM,  Annu Rev Biochem.  1992; 61 1213-30
• Regulating the myogenic regulators. Blau HM,  Symp Soc Exp Biol.  1992; 46 9-18
• Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Dhawan J,  Pan LC, Pavlath GK, Travis MA, Lanctot AM, Blau HM.  Science.  1991; 254 (5037): 1509-12
• Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Mantegazza R,  Hughes SM, Mitchell D, Travis M, Blau HM, Steinman L.  Neurology.  1991; 41 (7): 1128-32
• Differentiation requires continuous regulation. Blau HM,  Baltimore D.  J Cell Biol.  1991; 112 (5): 781-3
• Negative control of the helix-loop-helix family of myogenic regulators in the NFB mutant. Peterson CA,  Gordon H, Hall ZW, Paterson BM, Blau HM.  Cell.  1990; 62 (3): 493-502
• Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis. Kaplan I,  Blakely BT, Pavlath GK, Travis M, Blau HM.  Proc Natl Acad Sci U S A.  1990; 87 (20): 8100-4
• Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Webster C,  Blau HM.  Somat Cell Mol Genet.  1990; 16 (6): 557-65
• Cell lineage in vertebrate development. Blau HM,  Hughes SM.  Curr Opin Cell Biol.  1990; 2 (6): 981-5
• Migration of myoblasts across basal lamina during skeletal muscle development. Hughes SM,  Blau HM.  Nature.  1990; 345 (6273): 350-3
• Retroviral lineage markers for assessing myoblast fate in vivo. Blau HM,  Hughes SM.  Adv Exp Med Biol.  1990; 280 201-3
• Localization of muscle gene products in nuclear domains: does this constitute a problem for myoblast therapy? Blau HM,  Pavlath GK, Rich K, Webster SG.  Adv Exp Med Biol.  1990; 280 167-72
• Purification and proliferation of human myoblasts isolated with fluorescence activated cell sorting. Blau HM,  Webster C, Pavlath GK.  Adv Exp Med Biol.  1990; 280 97-100
• Effect of cell history on response to helix-loop-helix family of myogenic regulators. Schäfer BW,  Blakely BT, Darlington GJ, Blau HM.  Nature.  1990; 344 (6265): 454-8
• Localization of muscle gene products in nuclear domains. Pavlath GK,  Rich K, Webster SG, Blau HM.  Nature.  1989; 337 (6207): 570-3
• In vivo aging of human fibroblasts does not alter nuclear plasticity in heterokaryons. Pavlath GK,  Chiu CP, Blau HM.  Somat Cell Mol Genet.  1989; 15 (3): 191-202
• Tumor necrosis factor inhibits human myogenesis in vitro. Miller SC,  Ito H, Blau HM, Torti FM.  Mol Cell Biol.  1988; 8 (6): 2295-301
• Hierarchies of regulatory genes may specify mammalian development. Blau HM,  Cell.  1988; 53 (5): 673-4
• Muscle cell components dictate hepatocyte gene expression and the distribution of the Golgi apparatus in heterokaryons. Miller SC,  Pavlath GK, Blakely BT, Blau HM.  Genes Dev.  1988; 2 (3): 330-40
• Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Webster C,  Silberstein L, Hays AP, Blau HM.  Cell.  1988; 52 (4): 503-13
• Isolation of human myoblasts with the fluorescence-activated cell sorter. Webster C,  Pavlath GK, Parks DR, Walsh FS, Blau HM.  Exp Cell Res.  1988; 174 (1): 252-65
• In vivo system for characterizing clonal variation and tissue-specific gene regulatory factors based on function. Hardeman EC,  Minty A, Benton-Vosman P, Kedes L, Blau HM.  J Cell Biol.  1988; 106 (4): 1027-34
• Differential patterns of transcript accumulation during human myogenesis. Gunning P,  Hardeman E, Wade R, Ponte P, Bains W, Blau HM, Kedes L.  Mol Cell Biol.  1987; 7 (11): 4100-14